Readystate Asset Management LP Purchases 84,755 Shares of Lumexa Imaging Holdings, Inc. $LMRI

Readystate Asset Management LP grew its holdings in shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) by 60.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 224,755 shares of the company’s stock after buying an additional 84,755 shares during the period. Readystate Asset Management LP owned 0.23% of Lumexa Imaging worth $1,933,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. purchased a new position in Lumexa Imaging during the 4th quarter valued at about $37,139,000. Janus Henderson Group PLC purchased a new stake in Lumexa Imaging in the fourth quarter worth about $36,860,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Lumexa Imaging during the fourth quarter valued at approximately $27,750,000. ArrowMark Colorado Holdings LLC bought a new stake in shares of Lumexa Imaging in the 4th quarter worth approximately $27,750,000. Finally, Invesco Ltd. purchased a new stake in shares of Lumexa Imaging in the 4th quarter worth approximately $26,562,000.

Lumexa Imaging Trading Down 0.7%

Lumexa Imaging stock opened at $10.97 on Wednesday. The company has a market cap of $1.05 billion and a price-to-earnings ratio of -18.59. The business has a fifty day simple moving average of $9.95. Lumexa Imaging Holdings, Inc. has a 12 month low of $6.45 and a 12 month high of $19.45. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.43.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on LMRI shares. Wall Street Zen raised Lumexa Imaging from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Weiss Ratings upgraded shares of Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a research note on Thursday, June 25th. Finally, Barclays reduced their price objective on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.00.

Insider Activity at Lumexa Imaging

In other Lumexa Imaging news, Director Brett Brodnax acquired 35,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were bought at an average cost of $7.25 per share, with a total value of $253,750.00. Following the completion of the transaction, the director directly owned 62,027 shares of the company’s stock, valued at approximately $449,695.75. This represents a 129.50% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.70% of the stock is owned by company insiders.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).